Exploring the limits of conventional small-scale CHO fed-batch for accelerated on demand monoclonal antibody production.

In the field of therapeutic antibody production, diversification of fed-batch strategies is flourishing in response to the market demand. All manufacturing approaches tend to follow the generally accepted dogma of increasing titer since it directly increases manufacturing output. While titer is influenced by the biomass (expressed as IVCD), the culture time and the cell-specific productivity (q), we changed independently each of these parameters to tune our process strategy towards adapted solutions to individual manufacturing needs.